Dynamic Individualized Risk Profiling of Patients With Relapsed/Refractory Lymphoid Malignancies and CD19-CAR T Cell Therapy (INTeRCePT 2.0)

Inclusion Criteria: * Written informed consent before registration and prior to any trial specific procedures * Participants ≥ 18 years of age * Diagnosis of relapse/refractory B-cell lymphoma according to WHO 2022 classification * Measurable disease per response criteria specific to the disease e.g. per Lugano 2014 criteria * Patients planned for CD19-redirected CAR T cell therapy according to clinical standard of care * Patients who are willing to donate peripheral blood and biopsy material at indicated clinical visits Exclusion Criteria: * Any condition, which precludes initiation of CD19-redirected CAR T cell therapy (e.g. breast feeding, pregnancy, infections, etc.) as judged by the treating physician * Any coexisting medical or psychological condition that would preclude participation in the required study procedures, as judged by the treating physician * Unwillingness or inability to comply with the protocol